文献速递膀胱癌与上尿路尿路上皮癌

cT1微乳头状膀胱癌保膀胱治疗与早期根治性膀胱切除术的临床结局:系统综述与Meta分析

Clinical Outcomes of Bladder-sparing Management Versus Early Radical Cystectomy in cT1 Micropapillary Bladder Cancer: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol Oncol · 2026-10-20

该系统综述与Meta分析纳入9项回顾性研究共9402例患者,比较cT1微乳头状膀胱癌保膀胱治疗与早期根治性膀胱切除术的结局。汇总未调整风险比显示,两组在肿瘤特异性生存(HR 1.32,95%CI 0.60-2.88,p=0.5)和总生存(HR 0.85,95%CI 0.68-1.07,p=0.16)上均无统计学显著差异。

要点

  • cT1微乳头状膀胱癌保膀胱与早期RC的CSS和OS无显著差异
  • 保膀胱组88%接受膀胱内BCG治疗,BCG以外策略数据有限
  • 证据来自回顾性队列,需谨慎解读并个体化决策

核心结论

  • 在经选择的cT1微乳头状膀胱癌回顾性队列中,现有未调整数据未提供保膀胱治疗与早期RC在CSS或OS上存在统计学显著差异的明确证据。

研究设计与样本

  • 系统综述与Meta分析,遵循PRISMA声明和Cochrane手册,检索461篇报告后纳入9项回顾性研究,共9402例患者。
  • 9402例中9287例(99%)为非肌层浸润性膀胱癌,1033例(11%)为微乳头亚型。
  • 625例(62%)接受保膀胱治疗,392例(39%)接受早期根治性膀胱切除术。

主要发现

  • 保膀胱治疗对比早期RC的汇总未调整CSS风险比为1.32(95%CI 0.60-2.88,p=0.5),无统计学显著性。
  • 保膀胱治疗对比早期RC的汇总未调整OS风险比为0.85(95%CI 0.68-1.07,p=0.16),无统计学显著性。

关键数值与推荐

  • 保膀胱治疗中88%的患者接受膀胱内BCG治疗。
  • 评估BCG以外保膀胱策略的数据有限。

临床怎么用

  • 对于经选择的cT1微乳头状膀胱癌患者,现有回顾性证据未显示保膀胱治疗与早期RC在CSS或OS上有显著差异,可作为个体化决策的参考。
  • 保膀胱方案以膀胱内BCG为主,BCG以外策略的证据有限,选择时需谨慎。

局限性

  • 纳入研究均为回顾性设计,存在选择偏倚等固有局限。
  • 汇总分析采用未调整风险比,未充分控制混杂因素。
  • 评估BCG以外保膀胱策略的数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical T1 micropapillary urothelial carcinoma of the bladder is an aggressive variant histology for which early radical cystectomy (RC) is commonly recommended. However, there remain conflicting data on whether conditions in carefully selected patients may be managed with initial bladder-sparing approaches without compromising oncologic outcomes. OBJECTIVE: The objective is to systematically review and synthesize the available literature comparing bladder-sparing approaches, such as Bacillus Calmette-Guerin (BCG) therapy, and early RC outcomes in clinical stage 1 primary tumor (cT1) micropapillary carcinoma of the bladder. DESIGN, SETTING, AND PARTICIPANTS: A systematic search was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and Cochrane Handbook for Systematic Reviews of Interventions. OUTCOME MEASUREMENT AND STATISTICAL ANALYSIS: The primary end points were overall survival (OS) and cancer-specific survival (CSS). The included articles were descriptively assessed and time-to-event analysis was performed for select endpoints. RESULTS AND LIMITATIONS: Among 461 identified reports, nine retrospective studies met the criteria for quantitative analysis, encompassing 9402 patients of whom 9287 (99%) had non-muscle-invasive bladder cancer (NMIBC) and 1033 (11%) had a micropapillary subtype. A total of 625 patients (62%) underwent bladder-sparing approaches, whereas 392 (39%) underwent early RC. Of the bladder-sparing approaches, 88% of patients received intravesical BCG therapy. For a bladder-sparing approach for cT1 disease with a micropapillary component, pooled unadjusted hazard ratios were not statistically significant for CSS (hazard ratio [HR] 1.32, 95% confidence interval [CI] 0.60-2.88, p = 0.5) and OS (HR 0.85, 95% CI 0.68-1.07, p = 0.16) compared with early RC. Data evaluating bladder-sparing strategies beyond BCG were limited. CONCLUSIONS: NMIBC with micropapillary features is an aggressive disease conventionally managed with early RC. In retrospective cohorts of selected patients with micropapillary cT1, available unadjusted data did not provide clear evidence of statistically significant differences in CSS or OS between initial bladder-sparing approaches and early RC.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Patel SR, Rauf M, Geng Y, et al. Clinical Outcomes of Bladder-sparing Management Versus Early Radical Cystectomy in cT1 Micropapillary Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2026. PMID: 42901828. doi:10.1016/j.euo.2026.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。